Described herein are Bovine immunodeficiency virus gag protein (Bgag) recombinant virus like particles (VLPs) comprising one or more different types of target pathogen proteins. Also described, are compositions comprising the novel Bgag VLPs and the methods of making and using the novel Bgag VLPs.

Described herein are Bovine immunodeficiency virus gag protein (Bgag) recombinant virus like particles (VLPs) comprising one or more different types of target pathogen proteins. Also described, are compositions comprising the novel Bgag VLPs and the methods of making and using the novel Bgag VLPs.

Provided is a Spodoptera frugiperda pupa ovary cell line with high Baculovirus production. The cell line has the name of IOZCAS-Sf-1 and the deposit number of CGMCC No. 21014. Further disclosed are a method for preparing the cell line and the use of the cell line in the large-scale growth of the Baculovirus. The cell line can be used for replicating the Baculovirus, for the large-scale production of Baculovirus insecticides and for constructing a Baculovirus expression vector system.

The present disclosure is directed to a mammalian cell comprising an arthropod chemosensory receptor and its uses in methods of identifying repellents and attractants or traps for use in an arthropod control article comprising an arthropod control composition. The cell may be contained in a cell-based assay or disposed on a solid support.

The present disclosure is directed to a mammalian cell comprising an arthropod chemosensory receptor and its uses in methods of identifying repellents and attractants or traps for use in an arthropod control article comprising an arthropod control composition. The cell may be contained in a cell-based assay or disposed on a solid support.

Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

A baculovirus vector and a use thereof in the preparation of a recombinant adeno-associated virus (rAAV) in an insect cell are provided. The baculovirus vector includes an exogenous gene expression cassette and a stable sequence. The stable sequence is located at a site 5 kb or less from the exogenous gene expression cassette, and the stable sequence is a conserved noncoding element (CNE) sequence or a nucleocapsid assembly-essential element (NAE) sequence. When an insect cell is infected with a recombinant baculovirus (rBV) constructed in this way, after multiple continuous passages, production levels of the rBV and the rAAV still remain relatively stable.